Method of producing biologically active human acidic fibroblast growth factor and its use in promoting angiogenesis
AssigneeCardioVascular BioTherapeutics, Inc.
InventorsThomas J. Stegmann, Vitaliy A. Kordyum, Iryna Yu. Slavchenko, Svitlana I. Chernykh, Oleksandr F. Vozianov
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed.
Claims25
A method for revascularizing an ischemic region, comprising the steps of:
- (a) preparing a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 (FGF-1);
- and
- (b) injecting an amount of said pharmaceutical composition into the ischemic region, said amount being sufficient to induce local neoangiogenesis.
3-11. (canceled)
13-15. (canceled)
A method for treating coronary artery disease in a patient, comprising the steps of:
- (a) preparing a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 (FGF-1);
- (b) injecting an amount of said pharmaceutical composition into at least one site in a heart wall, said amount being sufficient to improve myocardial perfusion;
- and
- (c) injecting a composition comprising a physiological glue to a surface of the heart at the site(s) where the pharmaceutical composition was injected.
Dependencies are inferred from the claim text.